RxDoctor Payments DataLook up a doctor →

Alexander Marotta, MD

Allergy/ Immunology · Wyckoff, NJNPI 1720048077

Payments from drug & device makers

$12,112in general payments, 2019–2025

Across 600 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Sanofi$2K
  • Novartis$680
  • Regeneron Healthcare Solutions, Inc.$527
  • Optinose US, Inc.$518
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$8637%
  • Food & beverage$11,20392%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$25,157
Medicare patients
78
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$23,038
Spiriva HandihalerTiotropium Bromide13$12,639
Arnuity ElliptaFluticasone Furoate37$8,698
Advair HfaFluticasone Propion/Salmeterol11$8,189
Breo ElliptaFluticasone/Vilanterol18$7,291
Epinephrine17$2,530
Albuterol Sulfate HfaAlbuterol Sulfate24$1,665
Montelukast Sodium111$1,080
Azelastine-FluticasoneAzelastine/Fluticasone12$951
Mometasone Furoate16$759
Azelastine Hcl15$661
Fluticasone Propionate26$463
Levocetirizine Dihydrochloride22$301
Prednisone24$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta$1,761$39,02891 claims
Hikma Pharmaceuticals USAEpinephrine$28$2,53017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Wyckoff

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →